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Multiple sclerosis (MS) is an immune mediated inflammatory disease that attacks myelinated axons
in the central nervous system. Dalfampridine (4-aminopyridine) was approved by the Food and
Drug Administration in January 2010 for treatment of MS. Our patient was a 34-year-old male with a
history of MS, who was brought to the emergency department after being found unresponsive. His
current medications were valacyclovir, temazepam, dalfampridine (4-AP) and a tysabri intravenous
(IV) infusion. Fifteen minutes after arrival the patient seized. The seizures were refractory to
benzodiazepines, barbiturates and phenytoin. The 4-AP level was 530ng/mL (25ng/mL and 49ng/
mL). The patient stopped seizing on hospital day 3 and was discharged 14 days later with normal
mental status and neurologic exam. 4-AP is a potassium channel blocker that blocks the potassium
ion current of repolarization following an action potential. The blockade of the potassium channel at
the level of the membrane widens the action potential and enhances the release of acetylcholine,
thus increasing post-synaptic action potentials. The treatment of patients with 4-AP overdose is
supportive. Animal data suggest that patients with toxic levels of 4-AP may respond to phenytoin.
Our case illustrates the highest recorded level of 4-AP in an overdose. Our patient appeared to be
refractory to a combination of high doses of anticonvulsants and only improved with time. [West J
Emerg Med. 2015;16(7):1177-1179.]

INTRODUCTION

Multiple sclerosis (MS) is an immune-mediated
inflammatory disease that attacks myelinated axons in the
central nervous system. It is characterized by short-term
episodes of neurologic deficits that usually resolve completely
or almost completely. Patients with MS may suffer from pain
due to spasticity, fatigue and progressive disability.1 There is
currently no cure for the disease, but a plethora of treatments
are available and are continuously being developed.
One of the more novel medications on the market
is dalfampridine, or 4-aminopyridine (4-AP). 4-AP
was originally developed to be used as an avicide. The
chemical was studied in mammals and was shown to
cause hyperexcitability, hypersalivation, tremors, muscle
incoordination, convulsions, cardiac or respiratory distress.2
4-AP acts as a voltage-gated potassium channel blocker
that blocks the potassium ion current of repolarization in an
axon following an action potential. Potassium efflux out of the
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axon is the ionic mechanism that results in repolarization of the
axon. Repolarization must occur before the axon can generate
another action potential. In MS, the myelin sheath is thinned
and this results in either a weakened signal when the action
potential reaches its destination or a complete block. This leads
to weakness and fatigability of strength.3 The blockade of the
potassium channel widens the action potential, and thus 4-AP
increases the conduction of action potentials and this leads
to increased strength.2 Due to the ability of 4-AP to reverse
synaptic blockade it has been used as a treatment in many
different neuromuscular disorders such as Alzheimer’s disease,
botulism, Eaton Lambert syndrome and multiple sclerosis.4 In
January 2010, 4-AP was approved by the FDA in the United
States under the name dalfampridine to help patients with MS
improve their gait and strength when walking.5
There are always new medications being developed
for the treatment of MS, a disease with many potential
comorbidities; among them, depression is the most notable.
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This occurs in part because MS is a chronic disease and
also there are theories that it occurs because of frontal or
subcortical white matter disease.6 Here we present a case of a
4-AP overdose with the highest reported level in the literature.
CASE REPORT
A 34-year-old male with a past medical history of MS
was brought into the emergency department by Emergency
Medical Services after being found unresponsive by his
mother with three pill bottles at his side. The bottles were an
empty bottle of valacyclovir, an empty bottle of temazepam
and a bottle of dalfampridine still containing some pills. His
mother gave the history that the patient was under multiple
social stressors of late. Other than MS, the patient was
diagnosed with insomnia and had no other pertinent past
medical history. His current medications were valacyclovir,
temazepam, dalfampridine (4-AP) and a tysabri IV infusion
(all part of his MS treatment regimen).
The initial vital signs were as follows: Blood pressure:
155/82mmHg; Heart rate: 106/min; Respiratory rate: 24/min;
Temperature: 97.4oF; O2 sat: 97% 2L NC. The bedside glucose
was 144mg/dl. The patient appeared extremely tremulous, was
awake, but not responding to questioning nor following simple
commands. He responded to tactile stimulation by localizing to
the pain. He did not appear to have any focal deficits. His pupils
were 4 mm, equal and reactive and his mucous membranes
were moist. His heart sounds were tachycardic, with no
murmurs. The patient had clear breath sounds bilaterally and no
retractions. The abdomen had normoactive bowel sounds. The
skin was diaphoretic with piloerection.
Intravenous access was established, labs were drawn and
the patient was given two liters of normal saline. Soon after
arrival, the patient lost consciousness, his oxygen saturation
decreased to below 90% and he began to have a tonic-clonic
seizure. The patient was administered boluses of lorazepam,
to a total of 8 mg, without effect in seizure resolution. He
was intubated and subsequently placed on a lorazepam and
propofol infusion for sedation. He was loaded with one gram
of phenytoin and 300mg phenobarbital and then placed on
a phenobarbital infusion. Clinically the patient continued to
have frequent, recurrent seizures.
The patients lab values on arrival were significant
for a white blood cell count of 31.1×103/mcL, a sodium
of 143mEq/L, potassium 3.1mEq/L, chloride 107mEq/L ,
bicarbonate of 24mEq/L, a blood urea nitrogen of 15mg/
dL and a creatinine of 1.2mg/dL. The anion gap was 12.
The lactic acid was 3.4mg/dl. Total creatinine kinase was
99 units/L. Liver function tests and coagulation studies
were all within normal limits. Ethanol, acetaminophen
and salicylate levels were all negative. A urine toxicology
screen was positive for benzodiazepines. An arterial blood
gas showed pH 7.22, pCO2 65, pO2 127 and HCO3 26.6
(performed immediately after intubation). Computerized
tomography of the brain and chest x-ray were both normal.
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The electrocardiogram showed a sinus rhythm at 88 beats
per minute with normal QRS and QT intervals. Drug levels
were sent for 4-AP and valacyclovir. The 4-AP level resulted
at 530ng/mL (therapeutic: 25 to 49ng/mL). The valacyclovir
level was 7.5mcg/mL (therapeutic 2.0-4.0mcg/mL).
The patient was admitted to the intensive care unit (ICU)
and while he was there he continued to have seizures. While
in the ICU the patient had two electroencephalographs (EEGs)
performed. The EEG on hospital day 2 showed epileptiform
activity and the other EEG was performed on hospital day 7
and was indicative of epileptiform encephalopathy.
The patient stopped seizing on hospital day 3. The patient
was extubated on hospital day 12. He was discharged, with
normal mental status and neurologic exam to an inpatient
psychiatric facility.
DISCUSSION
Due to the fact that 4-AP is not a commonly used
medication, not much is known about how it acts at toxic
levels in humans. Van Diemen et al. looked at the dosage and
serum level related to efficacy and safety. During this study
a maximum daily dose of 0.5mg/kg body weight was not
surpassed in any patient. Patients in this study experienced
dizziness, paresthesias and restlessness at levels approaching
0.5mg/kg. No patient in the study had a seizure, as the level at
which seizures usually occur is 0.8mg/kg body weight.7
4-AP acts as a potassium channel blocker that prolongs
the action potential, thus increasing neuromuscular activity.
It is theorized that the increase in neuromuscular activity is
therapeutic at appropriate levels, but that the same mechanism
causes adverse reactions at elevated levels.8 The adverse reactions
are not only of the central nervous system, but also include injury
to the cardiac and skeletal muscle. One study showed that 4-AP
toxicity could result in permanent damage to the hippocampus
and Papez circuit affecting memory and learning.9
The 4-AP level of our patient resulted at 530ng/mL.
Until now, the highest documented 4-AP level published
was 233.6ng/mL.10 In that case, the patient was treated with
lorazepam boluses and the seizures subsided, as opposed to
our patient who was refractory to treatment with multiple
anti-convulsant medications. The valacyclovir level was
also elevated and valacyclovir itself can be associated
with neuropsychiatric symptoms. Seizures associated with
valacyclovir are not well reported in the literature, and the few
case reports on valacyclovir associated seizures are in patients
with renal failure, which our patient did not have.11,12
The current treatment of 4-AP overdose is supportive.
Animal data suggests that patients with 4-AP toxicity
will respond to phenytoin. It is hypothesized that because
phenytoin acts as a sodium channel blocker it will inhibit
action potentials from continuing.9 A study by Yamaguchi et
al.13 showed that treatment of mice with elevated levels of
4-AP with gamma butyric acid (GABA) was comparable to
other phenytoin-like therapies. Our patient did not respond to
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treatment with phenytoin. This raises the question of whether
or not a second phenytoin load should be used, or additional
anti-convulsants that have a similar mechanism of action to
phenytoin should be added.
Using phenytoin to treat seizures secondary to 4-AP is
an important concept because phenytoin is not usually part
of the algorithm for the treatment of toxin-induced seizures.
The recommendation for treating an undifferentiated toxininduced seizure is to use a benzodiazepine or barbiturate, then
pyridoxine and finally propofol.14 Toxin-induced seizures
differ from seizures from other causes because they usually
occur due to a global lowering of the seizure threshold in
previously normal neurons, whereas seizures due to epilepsy
occur in a focal lesion of abnormal neurons. Phenytoin is
effective for patients with idiopathic seizure disorders or
with defined structural or electrical foci of seizure activity,
as phenytoin prevents the propagation of seizures (include
reference). There are many reports of phenytoin used in toxininduced seizures causing clinical detriment to the patient.14
This case illustrates the highest recorded level of 4-AP in
an overdose. Optimal therapy for this overdose is unknown.
Our patient appeared to be refractory to a combination of high
dose intravenous benzodiazepines, phenytoin, propofol and
phenobarbital and only improved with time.
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